Dr. Gail J. Roboz

Dr. Gail J. Roboz, MD, is a leading authority in hematologic malignancies, specializing in the diagnosis and treatment of leukemia and related blood disorders. She is a Professor of Medicine at Weill Cornell Medical College and serves as the Director of the Clinical and Translational Leukemia Program at the Weill Cornell Medicine Meyer Cancer Center and NewYork-Presbyterian Hospital. Dr. Roboz earned her medical degree from Mount Sinai School of Medicine, completed her residency at NewYork-Presbyterian Hospital/Weill Cornell, and received fellowship training in hematology and medical oncology. Board-certified in internal medicine, hematology, and medical oncology, she provides personalized care to patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and other complex blood cancers.

Internationally recognized for her work in leukemia therapeutics and clinical trial leadership, Dr. Roboz has served as principal investigator for numerous groundbreaking studies involving novel agents and combination therapies for AML and MDS. Her translational research explores mechanisms of disease resistance and biomarkers for treatment response, contributing significantly to the advancement of personalized medicine in hematologic oncology. She collaborates closely with laboratory scientists and biopharmaceutical companies to accelerate the development of targeted therapies and immunotherapies, and her clinical expertise is widely sought in both academic and industry circles.

In addition to her clinical and research achievements, Dr. Roboz is an esteemed educator, lecturer, and media spokesperson for leukemia-related issues. She trains fellows and medical students in hematology-oncology and is frequently invited to speak at national and international conferences. Dr. Roboz has authored and co-authored hundreds of peer-reviewed publications, reviews, and book chapters. Her tireless dedication to improving outcomes for patients with blood cancers and her leadership in bringing novel treatments from bench to bedside have made her a prominent figure in the global hematologic oncology community.